Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study

Potential predictors of efficacy outcomes following tofacitinib dose reduction in patients with ulcerative colitis in stable remission: a post hoc analysis of outcomes from the RIVETING study

Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objectives: To investigate potential predictors of efficacy in RIVETING. Design: This post hoc analysis included patients with UC in stable remission (⩾6 months) on tofacitinib 10 mg twice daily (...

Full description

Saved in:
Bibliographic Details
Main Authors: Joana Torres, Geert R. D’Haens, Miguel Regueiro, Genoile Santana, Julian Panés, Séverine Vermeire, Sean Gardiner, Nicole Kulisek, Irene Modesto, Chinyu Su, Nervin Lawendy, Rajiv Mundayat, Jerome Paulissen, Marla C. Dubinsky
Format: Article
Language:English
Published: SAGE Publishing 2025-02-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848251318849
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17562848251318849

Similar Items